Lupin Pushes Fed. Circ. To Reconsider Fortamet Injunction

Law360, Washington (April 18, 2012, 8:02 PM EDT) -- Drugmaker Lupin Ltd. urged the Federal Circuit on Wednesday to reverse a preliminary injunction barring the company from selling its generic version of the diabetes drug Fortamet, saying its previous remand of the injunction had no effect on the lower court.

Sciele Pharma Inc., a unit of Shionogi Pharma Inc., sued the generic-drug maker in January 2009 after Lupin submitted an abbreviated new drug application to the U.S. Food and Drug Administration to make a generic version of Fortamet, a blood glucose-regulating drug.

While Lupin argued that the...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.